APA (7th ed.) Citation

N, C., MC, M., P, L., JA, S., G, J., C, S., . . . WA, G. (2021). Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: An open-label phase 2 study. Genetics in medicine : official journal of the American College of Medical Genetics, 23(11), 2067. https://doi.org/10.1038/s41436-021-01259-x

Chicago Style (17th ed.) Citation

N, Carrillo, et al. "Safety and Efficacy of N-acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-label Phase 2 Study." Genetics in Medicine : Official Journal of the American College of Medical Genetics 23, no. 11 (2021): 2067. https://doi.org/10.1038/s41436-021-01259-x.

MLA (9th ed.) Citation

N, Carrillo, et al. "Safety and Efficacy of N-acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-label Phase 2 Study." Genetics in Medicine : Official Journal of the American College of Medical Genetics, vol. 23, no. 11, 2021, p. 2067, https://doi.org/10.1038/s41436-021-01259-x.